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Purpose: To investigate equivalency of results from multivariable regression (MR) and 
propensity score matching (PSM) models, observational research methods used to mitigate 
bias stemming from non-randomization (and consequently unbalanced groups at baseline), 
using, as an example, a large study of chronic obstructive pulmonary disease (COPD) initial 
maintenance therapy.
Methods: Patients were 32,338 health plan members, age $40 years, with COPD initially treated 
with fluticasone propionate/salmeterol combination (FSC), tiotropium (TIO), or   ipratropium 
(IPR) alone or in combination with albuterol. Using MR and PSM methods, the proportion 
of patients with COPD-related health care utilization, mean costs, odds ratios (ORs), and 
incidence rate ratios (IRRs) for utilization events were calculated for the 12 months following 
therapy initiation.
Results: Of 12,595 FSC, 9126 TIO, and 10,617 IPR patients meeting MR inclusion criteria, 
89.1% (8135) of TIO and 80.2% (8514) of IPR patients were matched to FSC patients for the 
PSM analysis. Methods produced substantially similar findings for mean cost comparisons, 
ORs, and IRRs for most utilization events. In contrast to MR, for TIO compared to FSC, PSM 
did not produce statistically significant ORs for hospitalization or outpatient visit with antibiotic   
or significant IRRs for hospitalization or outpatient visit with oral corticosteroid. As in the MR 
analysis, compared to FSC, ORs and IRRs for all other utilization events, as well as mean costs, 
were less favorable for IPR and TIO.
Conclusion: In this example of an observational study of maintenance therapy for COPD, more 
than 80% of the original treatment groups used in the MR analysis were matched to comparison 
treatment groups for the PSM analysis. While some sample size was lost in the PSM analysis, 
results from both methods were similar in direction and statistical significance, suggesting that 
MR and PSM were equivalent methods for mitigating bias.
Keywords: multivariate analysis, outcomes research, propensity score, pulmonary disease, 
chronic obstructive, statistical bias, statistical models
Introduction
Although considered the “gold standard” for evaluating treatment effectiveness, 
  randomized clinical trials (RCTs) have important limitations. Because randomization 
removes potential bias from unknown and unmeasured confounders, observed differ-
ences in measured outcomes can be reasonably attributed to the treatment alone.1 For 
valid experimental reasons, however, RCTs frequently restrict enrollment based on 
existing comorbidities, treatment history, and disease severity, among other criteria. 
As a result, outcomes observed in RCTs cannot necessarily be generalized to the 
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“real world” of clinical practice, where patients present with 
  varying degrees of disease severity and a range of comor-
bidity profiles. While there has been a call for increasing 
the number of pragmatic clinical trials, trials that examine 
outcomes among diverse populations of patients in typical 
practice settings are still rare.2
Retrospective, observational studies are valuable because 
they contribute pragmatic knowledge about treatment 
risk, effectiveness, and cost in clinical practice settings – 
  knowledge that is critical to health care decision makers. 
In addition, observational studies are less costly and more 
quickly accomplished than RCTs, and can utilize large 
databases, permitting analysis of infrequent events. Because 
observational studies don’t involve randomization of patients 
to treatment groups, however, selection bias can occur, and 
unmeasured variables can confound the associations between 
treatments and outcomes.
Multivariable regression (MR) methods are commonly 
used to control for confounding factors in observational 
studies. Matching is an alternative strategy. It can be done 
at the individual level, as in case–control matching, or at the 
group or frequency level, as in stratified random sampling. 
The matching process involves diagnostic checks regarding 
the balance of covariates across groups and provides infor-
mation about the quality of the inferences that can be drawn 
from the subsequent analysis.3 Propensity score matching 
(PSM) has been increasingly used in epidemiologic   studies 
of medical treatment effectiveness.1 A propensity score 
represents the propensity of a particular subject to receive 
a particular treatment, based on the subject’s pre-treatment 
characteristics.1,4,5 The score combines many covariates into 
a single variable and enables individuals from each treatment 
group with similar covariate values to be matched, as a quasi-
randomization method.3 Subjects who cannot be matched are 
excluded from the analysis. An advantage of PSM is that 
matched sets with comparable covariate distributions can 
be created without the need for exact matches of each vari-
able, which is problematic when there are more than a few 
covariates.3 Propensity matching works best if there is a fairly 
large overlap between the groups in terms of propensity to 
be given a treatment. When there is not, underlying selection 
bias may exist.3 Despite this method’s theoretical benefits, in 
studies where both MR and PSM analysis methods have been 
used, only a small percentage of results (10% in one review 
and 13% in another) have been markedly different.1,6
Disease exacerbations are important events in the course 
of COPD. Moderate and severe exacerbations adversely affect 
lung function, potentially accelerating disease progression.7,8 
Frequency of exacerbations is a significant factor in 
  deteriorating health.9,10 Exacerbations also contribute sub-
stantially to health care utilization and costs. In the United 
States in 2010, the total cost of COPD was estimated to be 
US$49.9 billion. Direct medical costs were estimated to 
be $29.5 billion, including $13.2 billion for COPD-related 
hospital care.11 Reducing exacerbations is thus a singularly 
important goal of COPD management, both to improve 
patient quality of life and to reduce the indirect and direct 
medical costs of the disease. As pharmacotherapy is a primary 
means for reducing exacerbations, data concerning “real 
world” treatment effectiveness is of interest to health care 
providers, health care organizations, and health plans.
Agents for the relief and prevention of symptoms in 
COPD include short- and long-acting beta-agonists   (including 
albuterol and salmeterol), short-and long-acting anticholin-
ergics (including ipratropium bromide [IPR], tiotropium 
[TIO]), and inhaled corticosteroids (ICS).12 Fluticasone propi-
onate 250 µg/salmeterol 50 µg combination therapy (FSC) is 
an ICS plus long-acting beta-agonist used for treatment of air-
flow obstruction and reduction of exacerbations. Previously, 
we reported cost and utilization outcomes following initiation 
of COPD maintenance therapy with TIO, IPR (with or without 
albuterol), or FSC, using MR as the analysis method.13 To our 
knowledge, this was the first observational study to directly 
compare these three maintenance   therapies. Compared to TIO 
and IPR, FSC was associated with lower COPD-related costs 
and utilization (hospitalizations,   emergency department [ED] 
visits, and outpatient visits associated with an antibiotic or 
oral corticosteroid prescription). The objective of the present 
study was to perform a parallel analysis employing PSM to 
investigate the equivalency of results with those obtained in 
the prior MR analysis.
Materials and methods
Using PSM methods, we conducted a parallel analysis of 
COPD-related health care utilization and costs in patients 
with COPD receiving initial maintenance therapy (IMT) with 
FSC, TIO, or IPR, and we compared the results to those of a 
previous MR analysis. The term IMT refers to the patient’s 
first instance of a pharmacy claim for a COPD maintenance 
medication; prior to this point, the patient’s records indicated 
that he/she had not received maintenance therapy, only 
reliever medications or no medication.
We assessed exacerbations using claims data to 
  measure health care utilization events related to exacer-
bations. There is no universally accepted definition of 
  exacerbation. In clinical research, exacerbations generally are 
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defined in terms of worsening symptoms, unscheduled 
medical   attention, and courses of antibiotics and/or oral 
  corticosteroids.14 In observational studies such as ours, in 
which clinical and laboratory data are absent, exacerba-
tions typically have been defined in terms of COPD-related 
health care utilization events, including hospitalizations, ED 
visits, physician visits, and outpatient pharmacy fills for oral 
corticosteroids/antibiotics.
Data source
Administrative data were obtained from the IMS LifeLink 
Health Plan Claims Database (IMS Health, Watertown, 
WA), which contains enrollment and demographic data, 
and health care and outpatient pharmacy claims from more 
than 40 million members of more than 70 US health plans. 
Calculated costs were based on allowed amounts, which 
most closely resemble the direct health care cost burden of 
illness. This is typically the amount the health plan pays, 
plus any member liability (eg, co-payment, deductible, or 
coinsurance amount). For claims with missing charges due 
to capitation arrangements, charges are imputed by IMS. The 
dataset included patient demographic and enrollment data, 
outpatient pharmacy claims, and medical services claims 
(outpatient, ED, and inpatient claims, including both facility 
claims and professional services claims) for January, 2004 
to June, 2009. The specific content of the dataset has been 
described previously.13
Multivariable regression analysis
In the prior retrospective, observational cohort study, COPD-
related clinical and economic outcomes were evaluated in 
patients who received one of three IMT medications for 
COPD (FSC, TIO, or IPR).13 The study perspective was 
that of the health plan provider organization, and only 
direct costs were considered. The study population included 
health plan members with diagnosed COPD who were new 
to   maintenance therapy with FSC 250 µg/50 µg, TIO, or 
IPR (alone or in fixed dose combination with albuterol). 
The members were age 40 years and older, had a primary 
or secondary diagnosis of COPD (at least one ED visit, 
one hospitalization, or two outpatient visits with a pri-
mary or secondary International Classification of Disease, 
9th   edition, Clinical Modification [ICD-9-CM] diagnosis 
code of 491.xx, 492.xx, or 496.xx), had an IMT pharmacy 
claim between July 1, 2004 and June 30, 2008 (the date of 
the first identified   prescription claim was the “index date”), 
had at least 6 months of continuous health plan enrollment 
prior to the index date (the “baseline period”), and at least 
12 months of continuous enrollment following the index 
date (the “follow-up period”). Patients were excluded if 
they had a prescription drug fill for a COPD maintenance 
medication (FSC, IPR, TIO, budesonide/formoterol, inhaled 
corticosteroid alone, or long-acting beta-agonist alone) dur-
ing the baseline period, or a pharmacy fill for an alternate 
study IMT medication (FSC, TIO, or IPR) within 60 days of 
the index date. Patients were excluded if they had a primary 
or secondary diagnosis of respiratory tract cancer (larynx, 
trachea, or pleura [ICD-9-CM codes of 161, 161.x, 162, 163, 
163.x, 231, 231.x]) during the baseline period. The patient 
eligibility criteria and selection process have been described 
in detail previously.13
The primary utilization outcomes were incidence and 
mean number of COPD-related outpatient visits, outpatient 
visits associated with an antibiotic prescription fill,   outpatient 
visits associated with an oral corticosteroid fill, hospital-
izations, ED visits, and hospitalization and/or ED visits 
  (combined endpoint). Encounters with a primary diagnosis 
code of 491.xx, 492.xx, or 496 were defined as COPD-
related. The primary cost outcomes were mean COPD-related 
medical services costs, outpatient pharmacy costs (COPD 
controller and relief medications, oral corticosteroids, and 
antibiotics), and total costs (the sum of the two). Medical 
services costs comprised inpatient, outpatient, and ED care 
(including   facility charges and professional service fees). 
Costs were inflated to 2009 dollars on a monthly basis using 
the medical care portion of the US Consumer Price Index.15 
As outcomes were evaluated over a 12-month follow-up 
period, no discounting was applied to events or costs.
Bivariate analyses were used to compare differences 
between treatment cohorts in health care utilization and cost 
outcomes for the 12-month follow-up period. Multivariable 
logistic regression was used to model the risk for any health 
care utilization event as an odds ratio (OR). Negative bino-
mial and Poisson regression were used to calculate incidence 
rate ratios (IRRs). Because of the right-skewed nature of the 
cost distribution, a generalized linear model using a gamma 
distribution was used to estimate differences in treatment 
costs. Estimates of mean differences and 95% confidence 
intervals (CIs) were calculated from the predicted cost values. 
The multivariable models controlled for age, sex, treatment, 
comorbidities (including asthma and heart disease), and 
COPD-related health care utilization at baseline.
Propensity score matching analysis
Starting with the original patient sample identified for the MR 
analysis, we created matched cohorts for the PSM analysis. 
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The TIO patients and IPR patients were separately matched 
to FSC patients based on propensity score; that is, patients 
initiating therapy with TIO were matched to patients initiat-
ing with FSC, and patients initiating therapy with IPR were 
matched to patients initiating with FSC. The matched samples 
were created based on each patient’s predicted probability 
(propensity) of assignment to the case treatment (TIO or IPR). 
The propensity to be a patient whose initial maintenance 
therapy was TIO (or alternatively, IPR) incorporated the 
following baseline factors in the logistic regression   equation: 
sex, age category, geographic region, comorbidities, COPD-
related health care utilization, non-COPD-related health care 
utilization, COPD medication use, and COPD-related medi-
cal services costs. The utilization factors were hospitalization 
count and binary variables for outpatient visit, outpatient 
visit associated with an oral corticosteroid fill, outpatient 
visit associated with an antibiotic fill, ED visit, and hospi-
talization and/or ED visit (combined endpoint). Medication 
use was included using binary variables for short-acting 
beta-agonist (SABAs), oral corticosteroid, oral antibiotic, 
leukotriene modifier, and methylxanthine. Asthma, heart 
disease, and other relevant comorbidities were included as 
covariates. The greedy match algorithm was used, which 
performs matching using as much information as possible 
through the “nearest available pair” (or “nearest-neighbor”) 
matching method with a caliper component.16–18 Once 
a match is made, the greedy algorithm does not reconsider 
the match. Because no available matches could be identified 
for some patients in the original cohorts, the patient sample 
for the PSM analysis was a smaller subset of the sample used 
in the MR analysis.
The utilization and cost outcomes reviewed were the 
same as for the MR analysis. Bivariate analyses were used 
to compare differences in outcomes in the 12-month period 
following initiation of maintenance therapy for the FSC-TIO 
and FSC-IPR matched cohorts. Logistic regression was used 
to model the risk for any health care utilization event (OR), 
and negative binomial and Poisson regression were used to 
calculate IRRs. Mean cost differences and 95% CIs were 
assessed using least squares estimates from generalized linear 
models using a gamma distribution. Since the PSM treatment 
groups were already matched for baseline characteristics, 
and our interest was only in the treatment effect, the PSM 
regression models contained only a factor for case IMT (TIO 
or IPR), with FSC used as the reference medication.
For both the MR and PSM analyses, statistical tests 
were two-sided, with an α-level of 0.05 for statistical 
  significance. Demographic, clinical, and health care   utilization 
  characteristics were assessed as counts and percentages for 
categorical variables, and as standard measures (mean and 
SD) for continuous variables. Both unpaired and paired t-tests 
were used for determining significant differences in mean 
measures. The chi-square test and McNemar’s test were used 
to test paired proportion differences because significance 
tests that do not consider the non-independence of matched 
data have been found to be more conservative than tests for 
paired comparisons.19,20 Adequacy of matching was assessed 
using P values for comparison tests and standardized percent-
age differences.4,21 All analyses were conducted using SAS 
  software (v 9.2 for Windows; SAS Institute, Cary, NC).
Results
A total of 32,338 patients met patient selection criteria in the 
MR analysis: 12,595 FSC patients, 9126 TIO patients, and 
10,617 IPR patients. For the PSM analysis, 89.1% (8135) of 
the TIO patients were matched to FSC patients (64.6% of the 
original FSC cohort) and 80.2% (8514) of the IPR patients 
were matched to similar FSC patients (67.6% of the original 
FSC cohort). Figure 1 depicts the overlap in propensity scores 
between the groups. There was a large degree of overlap in 
the populations and good balance was achieved between the 
matched groups.
Baseline characteristics after matching
Baseline demographic, clinical, and utilization characteristics 
of the cohorts after matching on propensity score are shown 
in Table 1 (TIO-FSC) and Table 2 (IPR-FSC), along with 
P values for unpaired significance tests. Paired significance 
tests showed similar results although the P values were 
almost always lower (data not shown). After matching, the 
TIO and FSC groups were well balanced with respect to 
baseline characteristics; the groups were different only in 
mean COPD-related outpatient visits (P , 0.001). Matching 
between the IPR and FSC patients involved more factors. 
After matching, differences were present for some base-
line characteristics: mean COPD-related outpatient visits 
(P = 0.02), mean all-cause outpatient visits (P , 0.001), 
and mean days’ supply of SABAs (P = 0.007). Figures 2 
and 3 show absolute standardized difference percentages 
for baseline characteristics prior to and after matching. 
These graphs further illustrate that, while some significant 
differences remained after matching, they were small from 
a clinical standpoint. Absolute standardized percentage 
differences were less than 10% for all assessed baseline 
characteristics in both groups, supporting an assessment of 
balance between groups.22
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Figure 1 Overlap between FSC and TIO (top graph) and FSC and IPR (bottom graph) groups for calculated probability to receive TIO or IPR treatment.
Notes: Probability was calculated using logistic regression and adjusted for baseline covariates. The large intersection of the TIO and FSC distributions (89.1% of TIO patients 
matched) and IPR and FSC distributions (80.2% of IPR patients matched) indicates a high degree of similarity on the measured attributes.
Abbreviations: FSC, fluticasone propionate/salmeterol combination; IPR, ipratropium; TIO, tiotropium.
We compared differences in baseline   characteristics between 
excluded patients and matched patients (Figures 2 and 3). 
Characteristics with large differences between excluded and 
matched patients tended to be the same characteristics as 
those associated with large standardized differences prior to 
matching. The excluded TIO and IPR patients were older, and 
had more comorbidities and higher health care utilization. 
The excluded TIO patients, when compared to FSC patients 
who were not matched to TIO patients, were older (mean, 
66.9 vs 60.1 years, P , 0.001) and more likely to be male 
(68.7% vs 39.8%, P , 0.001), not to have asthma (4.4% vs 
46.8%, P , 0.001), to have lower use of leukotriene modifiers 
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Health care utilization and costs
Utilization and cost outcomes in the 12 months following 
initiation of maintenance therapy are shown in Table 3 and 
Figure 4, respectively. For the utilization comparisons, the 
more conservative unpaired significance tests were used. 
As described above, some subjects in the original MR 
cohorts were excluded from the PSM cohorts during the 
matching process. Those excluded were predominantly 
Table 1 Demographic and clinical characteristics of tiotropium 
and  fluticasone  propionate/salmeterol  cohorts  matched  on 
propensity score
FSC 
n = 8135
TIO 
n = 8135
P valuea
Age, mean (SD) 64.3 (11.57) 64.2 (11.37) 0.48
Male, n (%) 4173 (51.3) 4187 (51.5) 0.83
Comorbid conditions, n (%)
Alcohol abuse 116 (1.4) 130 (1.6) 0.37
Anemia 87 (1.1) 90 (1.1) 0.82
Arrhythmia 1103 (13.6) 1111 (13.7) 0.85
Asthma 1017 (12.5) 1071 (13.2) 0.21
Congestive heart failure 999 (12.3) 1018 (12.5) 0.65
Diabetes (uncomplicated) 1554 (19.1) 1554 (19.1) 1.00
Fluid disorders 561 (6.9) 605 (7.4) 0.18
Heart disease 2020 (24.8) 2047 (25.2) 0.62
Hypertension  
(uncomplicated)
4010 (49.3) 4054 (49.8) 0.49
Hypothyroidism 692 (8.5) 667 (8.2) 0.48
Obstructive sleep apnea 624 (7.7) 629 (7.7) 0.88
Other lung conditions 1698 (20.9) 1750 (21.5) 0.32
Other neurological disease 255 (3.1) 237 (2.9) 0.41
Renal failure 335 (4.1) 335 (4.1) 1.00
Valvular disease 840 (10.3) 845 (10.4) 0.90
Rescue medicine use, n (%)
SABA use 1677 (20.6) 1662 (20.4) 0.77
COPD-related utilization, number of encounters: mean (SD)
Outpatient visit 0.58 (1.13) 0.64 (1.25) 0.001
Outpatient visit with  
antibiotic
0.06 (0.28) 0.06 (0.29) 1.00
Outpatient visit with oral  
corticosteroid
0.03 (0.20) 0.03 (0.24) 0.75
ED visit 0.02 (0.15) 0.02 (0.16) 0.58
Hospitalization 0.05 (0.24) 0.06 (0.24) 0.60
Hospitalization or ED visit 0.08 (0.29) 0.08 (0.29) 0.46
COPD-related costs ($US), mean (SD)
Medical servicesb 958 (6346) 982 (5780) 0.81
Pharmacy 34 (113) 35 (112) 0.40
Total 992 (6346) 1017 (5781) 0.80
Notes: aCalculated using chi-square test for frequencies and t-test for continuous 
measures, P values for cost measures are calculated using the Wilcoxon rank-sum 
test; bhealth care facility charges and professional services fees.
Abbreviations: COPD, chronic obstructive pulmonary disease; ED, emergency 
department;  FSC,  fluticasone  propionate/salmeterol  combination;  SABA,  short-
acting beta-agonist; TIO, tiotropium.
Table 2 Demographic and clinical characteristics of ipratropium 
and  fluticasone  propionate/salmeterol  cohorts  matched  on 
propensity score
  FSC  
n = 8514
IPR  
n = 8514
P valuea
Age, mean (SD) 64.0 (12.03) 64.2 (12.15) 0.29
Male, n (%) 4173 (49.0) 4090 (48.0) 0.20
Comorbidities, patients with diagnosis: n (%)
Alcohol abuse 142 (1.7) 139 (1.6) 0.86
Anemia 85 (1.0) 93 (1.1) 0.55
Arrhythmia 1173 (13.8) 1192 (14.0) 0.67
Asthma 1269 (14.9) 1324 (15.6) 0.24
Congestive heart failure 1132 (13.3) 1156 (13.6) 0.59
Depression 615 (7.2) 620 (7.3) 0.88
Diabetes (uncomplicated) 1854 (21.8) 1865 (21.9) 0.84
Fluid disorders 729 (8.6) 746 (8.8) 0.64
Heart disease 2060 (24.2) 2099 (24.7) 0.49
Hypertension  
(uncomplicated)
4191 (49.2) 4230 (49.7) 0.55
Hypothyroidism 679 (8.0) 701 (8.2) 0.54
Obstructive sleep apnea 601 (7.1) 560 (6.6) 0.21
Other lung conditions 1730 (20.3) 1800 (21.1) 0.19
Other neurological disease 299 (3.5) 302 (3.5) 0.90
Pulmonary circulation 206 (2.4) 212 (2.5) 0.77
Renal failure 393 (4.6) 395 (4.6) 0.94
Valvular disease 864 (10.1) 878 (10.3) 0.72
Weight loss 50 (0.6) 72 (0.8) 0.05
Rescue medicine use, n (%)
SABA use 1296 (15.2) 1320 (15.5) 0.61
COPD-related utilization, number of encounters: mean (SD)
Outpatient visit 0.48 (1.08) 0.52 (1.22) 0.02
Outpatient visit with  
antibiotic
0.07 (0.29) 0.07 (0.30) 0.23
Outpatient visit with oral  
corticosteroid
0.04 (0.24) 0.04 (0.23) 0.87
ED visit 0.03 (0.18) 0.03 (0.18) 0.93
Hospitalization 0.06 (0.25) 0.06 (0.26) 0.32
Hospitalization or ED visit 0.09 (0.31) 0.09 (0.31) 0.44
COPD-related costs ($US), mean (SD)
Medical servicesb 998 (6318) 1080 (6692) 0.42
Pharmacy 31 (106) 34 (138) 0.11
Total 1029 (6319) 1114 (6692) 0.40
Notes: aCalculated using chi-square test for frequencies and t-test for continuous 
measures, P values for cost measures are calculated using the Wilcoxon rank-sum 
test; bhealth care facility charges and professional services fees.
Abbreviations: COPD, chronic obstructive pulmonary disease; ED, emergency 
department; FSC, fluticasone propionate/salmeterol combination; IPR, ipratropium; 
SABA, short-acting beta-agonist. (2.4% vs 12.6%, P , 0.001), and SABAs (15.4% vs 32.9%, 
P , 0.001), and to have significantly higher COPD-related 
medical service costs (US$3734 vs $365, P , 0.001). 
Similarly, excluded IPR patients, when compared to FSC 
patients not matched to IPR patients, were older (68.6 vs 60.4 
years, P , 0.001) and more likely to be male (58.4% vs 37.0%, 
P , 0.001), not to have asthma (6.6% vs 45.3%, P , 0.001), 
to have lower use of leukotriene modifiers (1.5% vs 14.6%, 
P , 0.001) and SABAs (6.2% vs 45.1%, P , 0.001), and to 
have significantly higher COPD-related medical service costs 
($5437 vs $220, P , 0.001).
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older (and costlier) TIO and IPR patients, and younger 
FSC patients. This resulted in changes in the frequencies 
and means for   outcomes in all treatment groups in the 
PSM analysis.   However, the shifts for utilization para-
meters tended to be small. For example, in the MR analysis,   
3.6% of FSC patients, 4.7% of TIO patients, and 7.3% of IPR 
patients had one or more ED visit (P , 0.001 for all differ-
ences between TIO and FSC and between IPR and FSC).19 In 
the TIO-FSC PSM analysis, 3.4% of FSC patients and 4.5% 
of TIO patients had one or more ED visit. In the IPR-FSC 
PSM analysis, 3.8% of FSC patients and 6.6% of IPR patients 
had one or more ED visit (P , 0.001 for both comparisons). 
Thus, in both analysis methods, the incidence of ED visits was 
lower in the FSC group, and differences between treatment 
groups were similar in magnitude. The excluded FSC patients 
had almost no impact on mean cost estimates for patients 
treated with FSC. However, for patients treated with TIO 
and IPR, the exclusion of older and sicker patients resulted 
in lower cost estimates for COPD-related medical services 
and total COPD-related costs (Figure 4).
TIO versus FSC
Several significant differences between the TIO and FSC 
groups seen in the MR analysis were also seen in the 
PSM analysis. The FSC group had a lower percentage of 
patients with an outpatient visit, outpatient visit associated 
with an oral corticosteroid, ED visit, or hospitalization/ED 
visit. In contrast to the MR analysis, the PSM analysis found 
no difference in the percentage of patients with a hospital-
ization (P = 0.25) or outpatient visit associated with an oral 
corticosteroid (P = 0.08). For each outcome measure, the 
percentage of patients with an encounter was lower in the 
FSC cohort than in the TIO and IPR cohorts, although, in 
the PSM analysis, because of the excluded younger FSC and 
older TIO patients, the FSC percentages increased slightly 
and the TIO percentages decreased slightly, diminishing 
the absolute differences between the two groups. With the 
exception of pharmacy costs, differences in costs that were 
significant in the MR analysis were also significant in the 
PSM analyses. FSC was associated with lower medical 
services costs (FSC, US$1085 [95% CI: $1061–1108]; TIO, 
Age
Male
Dx arrythmia
Dx asthma
Dx CHF
Dx diabetes
Dx heart disease
Dx hypertension
Dx other lung condition
Dx sleep apnea
Dx valvular disease
Any SABA use
Any leukotriene modifier use
Outpt with antibiotic
Outpt with OCS
ED visit
COPD pharmacy costs
COPD total costs
Pre-matching
Post-matching
051 01 5
Absolute standardized difference (%)
20 25 30 35
COPD medical services costs
Hospitalization/ED
Hospitalization
Outpt
Figure 2 Standardized differences (percentages) in baseline characteristics between tiotropium and fluticasone propionate/salmeterol groups before and after matching.
Abbreviations: CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; Dx, diagnosis; ED, emergency department; OCS, oral corticosteroid; Outpt, 
outpatient; SABA, short-acting beta-agonist.
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Age
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Figure 3 Standardized difference percentages in baseline characteristics between ipratropium and fluticasone propionate/salmeterol groups before and after matching.
Abbreviations: CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; Dx, diagnosis; ED, emergency department; OCS, oral corticosteroid; Outpt, 
outpatient; SABA, short-acting beta-agonist.
US$1316 [95% CI: $1288–1345]), and total health care costs 
compared to TIO (FSC, $2037 [95% CI: $1993–2081]; TIO, 
US$2267 [95% CI: $2218–2316]).
IPR versus FSC
The original MR analysis found that, in each of the five 
categories of utilization events, a lower percentage of FSC 
patients compared to IPR patients experienced events. These 
findings were essentially duplicated in the PSM analysis, 
despite the exclusion of 20% of the IPR patients. (P values 
for all differences were ,0.001 in the MR analysis, and 
ranged from ,0.001 to 0.03 in the PSM analysis).   Differences 
in COPD-related costs that were significant in the MR 
analysis were also significant in the PSM analysis. FSC was 
associated with higher pharmacy costs (FSC, $917 [95% 
CI: $897–936]; IPR, US$614 [95% CI: $601–627]), but lower 
medical service costs (FSC, $1122 [95% CI: $1099–1146]; 
IPR, US$1746 [95% CI: $1709–1784]), and total costs com-
pared to IPR (FSC, US$2039 [95% CI: $1996–2083]; IPR, 
US$2360 [95% CI: $2311–2411]).
Risk for health care utilization
The ORs for health care utilization are shown in Figure 5. The 
MR and PSM analyses produced fairly similar ORs for vari-
ous categories of health care utilization, with ORs produced 
by the PSM analysis being slightly lower. For example, in 
the MR analysis, the statistically significant hospitalization/
ED visit ORs for TIO and IPR (with respect to FSC) are 1.28 
and 1.72, respectively; these values are 1.21 and 1.67 in the 
PSM analysis, respectively. Nonetheless, both analyses show 
that TIO and IPR patients have higher ORs, compared to FSC 
patients, for outpatient visit, outpatient visit with oral corti-
costeroid, ED visit, and hospitalization/ED visit. The IPR and 
FSC comparison also showed higher ORs for hospitalization 
and for an outpatient visit with an antibiotic. However, while 
the MR analysis calculated slightly higher odds for hospital-
ization for TIO (OR: 1.19 [95% CI: 1.04–1.37]) compared to 
FSC, the PSM analysis found no difference (OR: 1.10 [95% 
CI: 0.94–1.28]), nor was any difference in risk found between 
TIO and FSC for an outpatient visit with an antibiotic (OR: 
1.14 [95% CI: 0.98–1.32]).
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Table 3 Number of patients with COPD-related health care utilization in the 12 months following therapy initiation: comparison of 
TIO to FSC and IPR to FSC using two analysis methods
COPD-related utilization category Multivariable regression analysis13  
patients with any encounter: n (%)
Propensity score-matched analysis,  
patients with any encounter: n (%)
FSC  
n = 12,595
TIO  
n = 9126
P valuea FSC  
n = 8135
TIO  
n = 8135
P valuea
Outpatient visit 3615 (28.7) 3661 (40.1) ,0.001 2567 (31.6) 3147 (38.7) ,0.001
Outpatient visit with antibiotic 490 (3.9) 478 (5.2) ,0.001 355 (4.4) 402 (4.9) 0.08
Outpatient visit with oral corticosteroid 261 (2.1) 262 (2.9) 0.001 178 (2.2) 224 (2.8) 0.02
ED visit 450 (3.6) 427 (4.7) ,0.001 277 (3.4) 366 (4.5) ,0.001
Hospitalization 446 (3.5) 413 (4.5) ,0.001 314 (3.9) 343 (4.2) 0.25
Hospitalization/ED visit 819 (6.5) 764 (8.4) ,0.001 544 (6.7) 647 (8.0) 0.002
FSC  
n = 12,595
IPR  
n = 10,617
P valuea FSC  
n = 8514
IPR  
n = 8514
P valuea
Outpatient visit 3615 (28.7) 3788 (35.7) ,0.001 2501 (29.4) 2940 (34.5) ,0.001
Outpatient visit with antibiotic 490 (3.9) 617 (5.8) ,0.001 358 (4.2) 454 (5.3) ,0.001
Outpatient visit with oral corticosteroid 261 (2.1) 354 (3.3) ,0.001 189 (2.2) 269 (3.2) ,0.001
ED visit 450 (3.6) 778 (7.3) ,0.001 322 (3.8) 566 (6.6) ,0.001
Hospitalization 446 (3.5) 651 (6.1) ,0.001 328 (3.9) 475 (5.6) ,0.001
Hospitalization/ED visit 819 (6.5) 1284 (12.1) ,0.001 594 (7.0) 945 (11.1) ,0.001
Notes: aCalculated using chi-square test.
Abbreviations: COPD, chronic obstructive pulmonary disease; ED, emergency department; FSC, fluticasone propionate/salmeterol combination; IPR, ipratropium; TIO, 
tiotropium.
Incidence rate ratios
The IRRs for health care utilization events in the TIO and 
IPR groups with reference to the FSC group are shown in 
Figure 5. Again, both analytic methods yielded fairly simi-
lar IRRs, with the PSM analysis producing slightly lower 
IRRs for all categories of utilization. In all comparisons in 
the PSM analysis, as in the MR analysis, IPR patients were 
found to be at significantly higher risk for events, compared 
to FSC patients. For the TIO group compared to the FSC 
group, all IRRs in the MR analysis were significantly higher. 
However, in the PSM analysis, IRRs for outpatient visits 
with oral corticosteroid and for hospitalizations were no 
longer significant.
Discussion
In this analysis of data from an observational, retrospective 
cohort study of initial maintenance therapies for COPD, we 
demonstrated the similarity of results using two analytic 
approaches to observational research. Specifically, we 
compared results from a PSM analysis with those from a 
previously published, parallel MR analysis.13 We found 
that both methods yielded similar health care utilization 
and cost outcomes. General agreement between MR and 
PSM methods has been found in other studies. In a review 
of 177 comparative method studies, Sturmer concluded that 
substantial changes in treatment effects were seen when point 
estimates were calculated with and without adjustment for 
covariates, but that the method of adjustment itself – MR or 
PSM – made little difference.1
In PSM, a high degree of propensity score overlap after 
matching is desirable in terms of internal validity. When 
overlap is minimal, unmeasured confounding bias in treat-
ment groups probably cannot be resolved using either MR 
or PSM techniques.1 In the present PSM analysis, large pro-
portions of patients in both the TIO and IPR cohorts (89.1% 
and 80.2%, respectively) were matched to FSC patients, and 
there was substantial overlap in propensity scores between 
groups. In other words, matching produced cohorts with 
similar baseline characteristics. In general, the few statisti-
cally significant differences remaining after matching were 
minor in terms of effect size and practical significance, and 
had small absolute standardized differences. Characteristics 
that would be expected to considerably skew utilization 
outcomes, such as comorbid cardiovascular disease, were 
not different between matched groups.
Outcomes differed slightly between the PSM and MR 
analyses. Some differences may be due to the smaller PSM 
sample size, since the excluded patients were a contribut-
ing explanatory factor for the lower PSM utilization and 
cost estimates. While the MR analysis was a population-
based study, the PSM analysis, as a result of the matching 
process, excluded some younger individuals, with minimal 
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Figure 4 COPD-related health care costs in the 12 months following therapy initiation: comparison of TIO and IPR to FSC using two analysis methods.
Notes: Bars depict mean cost (2009 $US) and 95% confidence interval. Medical services costs include health care facility charges and professional services fees; *P , 0.001; 
**P , 0.05 (unpaired t-test).
Abbreviations: FSC, fluticasone propionate/salmeterol combination; IPR, ipratropium; MR, multivariable regression; PSM, propensity score matching; TIO, tiotropium.
  comorbidities, who were treated with FSC, and some older, 
sicker individuals who were treated with IPR or TIO. 
  Exclusion of the older and sicker individuals resulted in 
lower mean costs for IPR and TIO patients, while costs for 
FSC patients were quite similar in both analyses.
Event frequency also may be a factor in the differences 
in findings between analysis methods. Multivariable logis-
tic regression and propensity matching have been found to 
produce similar results when events are not infrequent.23–25 
Through simulations, Cepeda and colleagues found that 
the use of propensity scores yielded less biased estimates 
than multivariable logistic regression only when there were 
eight or fewer modeled events per covariate.26 When the 
ratio of modeled events was higher, multivariable logistic 
  regression was the better method. Other studies have deter-
mined that ten events per covariate is a desired ratio when 
using maximum likelihood methods.27 The main outcomes 
in our analyses, (COPD-related outpatient visits associated 
with an antibiotic or oral corticosteroid, ED visits, and hos-
pitalizations), although of great concern clinically, occur 
relatively infrequently, from a statistical standpoint, when 
averaged across a large population of COPD patients that is 
unrestricted in terms of disease severity. Our original MR 
analysis included 44 covariates. The outcome of outpatient 
visit with an oral corticosteroid had the smallest number of 
events per covariate modeled, with 877 of 32,338 patients 
having at least one event, which translates to 20 events per 
covariate in the multivariate logistic regression analysis. 
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Figure 5 Risk (left graph) and incident rate ratios (right graph) for any health care encounter in the 12 months following therapy initiation: evaluation of TIO and IPR (with 
reference to FSC) using two analysis methods.
Abbreviations: ED, emergency department; FSC, fluticasone propionate/salmeterol combination; IPR, ipratropium; OCS, oral corticosteroids; Outpt, outpatient; TIO, 
tiotropium.
This compares to 65 events per covariate for the combined 
endpoint of hospitalization/ED visit. The lower ratios of 
events per covariate for some outcomes may have been a 
factor in the different findings of the two analyses for ORs 
and IRRs. On the other hand, costs (COPD-related medical 
service costs and pharmacy costs) were universally incurred, 
and both analyses found that, compared to FSC, TIO and IPR 
were associated with higher costs for COPD-related medical 
services, and higher total costs, even though costs associated 
with TIO and IPR were reduced in the PSM analyses.
Both MR and PSM methods adjust associations between 
treatment effects and outcomes to reduce potential bias from 
observed covariates. Other researchers have reported that 
results from the two methods appear to be consistent when 
there is large overlap between groups in propensity for a 
given treatment, which ensures minimal loss of observations, 
and when outcomes can be modeled with a relatively large 
number of events per covariate.1,4,24 Our findings support this 
view and suggest that, with regard to less frequent events, 
in particular when effect sizes may be small, consideration 
should be given to analyzing outcomes using both methods, 
assuming a large proportion of subjects can be matched.
While PSM is a more transparent method, in the sense that 
it allows one to see the degree of equality between groups 
after matching, in this study, PSM provided little advantage 
over MR in terms of the validity of the results. Because 
of the inevitable reduction in sample size and change in 
overall composition of treatment groups being compared, 
the choice of whether to use PSM or MR will depend on the 
question being investigated, whether a population effect is 
being measured, and whether review of a non-representative 
population of patients receiving treatment is acceptable 
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(or even preferred). This point is addressed by D’Agostino, 
who recommended that when patients are excluded in 
matched analyses, researchers need to be particularly clear in 
their descriptions of the included and excluded patients, and 
of the populations to which study results are applicable.28
Strengths of this study include the large sample sizes of 
both analyses and the high degree of propensity matching, 
with approximately 80% and 89% of the original IPR and TIO 
cohorts matched, respectively, to FSC patients. The exclusion 
of some original subjects from the PSM cohorts due to lack of 
a match does mean, however, that any additional information 
these subjects might have provided was lost, and statistical 
power affected. Some limitations should be considered in 
interpreting the results. We measured exacerbations using 
claims data, defining exacerbations as COPD-related health 
care events. Using an alternative definition of exacerbation 
based on symptoms, lung function, or other clinical para-
meters could influence observed effect sizes.14 However, we 
would not expect a different definition of exacerbations to 
influence effect sizes differently for MR than for PSM, or 
for it to change the overall findings of this study. Since both 
MR and propensity matched analyses attempt to reduce bias 
through adjustment using covariates, the ability to do this 
is dependent on the capture of all relevant factors. In this 
analysis, some potential confounders were unmeasured. 
As this was an observational study utilizing administrative 
claims data, information about patients’ clinical status was 
not available. We could not ascertain lung function status, 
disease severity, or other clinical characteristics. Therefore, 
residual baseline differences between treatment groups 
may remain. However, we did control for two key char-
acteristics of interest – disease severity and exacerbation 
frequency – by using prior COPD-related health care and 
pharmacy utilization (particularly oral corticosteroids/ 
antibiotics) as proxy measures.
Conclusion
Results obtained in our analysis suggest that both MR 
and PSM methods are appropriate analytic techniques for 
addressing and mitigating bias in observational research. 
In this example of an observational study of maintenance 
therapy for COPD, more than 80% of the original treatment 
groups used in the MR analysis were matched to a comparison 
group for the PSM analysis. While some sample size was 
lost in the PSM analysis, results from both methods were 
similar in direction and statistical significance. Further, this 
analysis underscores the need for researchers to have a good 
understanding of the populations undergoing treatment and 
the factors associated with both receipt of treatment and 
occurrence of the measured outcomes.
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